Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Johnson and Johnson International (Singapore) Pte Ltd, - Pioneering advances in EGFRm NSCLC therapy: Navigating the future of patient care

Panel discussion and Q&A

Date

07 Dec 2024

Session

Johnson and Johnson International (Singapore) Pte Ltd, - Pioneering advances in EGFRm NSCLC therapy: Navigating the future of patient care

Presenters

Ross Soo, Tony S.K. Mok, Alexander Spira

Authors

R.A. Soo1, T.S.K. Mok2, A.I. Spira3

Author affiliations

  • 1 Haematology-oncology Department, NCIS - National University Cancer Institute Singapore, 119074 - Singapore/SG
  • 2 Clinical Oncology Department, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin/HK
  • 3 Research Department, Virginia Cancer Specialist, 22031 - Fairfax/US

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.